What are the signs that controlled substance prescribing still needs modernization?

A strong warning sign is the continued use of dual workflows, where clinicians must manage both paper and electronic prescribing paths. Another signal is low adoption even when the technology exists, especially if providers avoid it because the process disrupts care. If patients still need repeated pharmacy trips and staff still spend time on manual handling, the workflow is not yet optimized.

What signals that controlled substance prescribing is still not modernized?

The clearest signal is that the workflow still forces people to split attention between old and new processes instead of relying on one reliable path. When adoption stays low despite available technology, or when the process creates extra trips, extra manual handling, and more staff effort than the clinical value warrants, the system is lagging behind modern prescribing practice.

Why dual workflows are the biggest warning sign

Dual workflows are more than an inconvenience. They usually mean the organisation has not fully removed the operational drag of paper and electronic prescribing running side by side, so clinicians, pharmacies, and staff must reconcile two different ways of doing the same task. That creates inconsistency, slows care, and makes it harder to standardise compliance, verification, and handoff steps.

In practical terms, a modernised process should make the normal path the easiest path. If the clinician still has to decide case by case whether to use paper or electronic methods, or if policy exceptions are so common that they feel routine, the workflow has not been simplified enough to scale cleanly.

What low adoption and manual handling reveal

Low adoption is a useful indicator only when the underlying capability already exists. If providers avoid the electronic workflow because it disrupts care, adds friction at the point of prescribing, or fails to fit clinical reality, then the technology has not been embedded well enough to replace the legacy pattern.

Repeated pharmacy trips and ongoing manual handling are especially strong signs that the system is not yet optimised. They show that the prescribing process still depends on avoidable human effort, which usually means the design is not aligned with how prescriptions should move from order to fulfillment with minimal rework, delay, or transcription risk.

What a modernised prescribing workflow should look like instead

A modernised workflow reduces the number of steps, the number of handoffs, and the number of reasons a prescription can stall. The clinician should be able to complete the right action once, the patient should not have to compensate for process gaps, and staff should not need to bridge routine gaps by phone, paper chasing, or repeated exception handling.

That does not mean every prescription looks identical. Controlled substance workflows still need checks, but the checks should be built into the primary path rather than bolted on as parallel work. When the control model is mature, the workflow feels consistent enough that exceptions stand out instead of being the norm.

Risk and Threat Considerations

Legacy prescribing patterns increase both operational and security exposure because they multiply the number of places where errors, delays, and unauthorized handling can occur. They also make it harder to see whether a prescription moved through the intended path, which weakens oversight and can leave gaps in accountability.

Failure mechanism: A split paper-and-electronic process creates inconsistency in verification, routing, and recordkeeping, so legitimate orders can be delayed while manual workarounds or exceptions become normal.

Impact: Patients face more friction and delays, staff absorb unnecessary handling burden, and the organisation loses the control and visibility expected from a modern prescribing workflow.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

CIS Controls v8 and NIST SP 800-53 Rev 5 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.

Framework	Control / Reference	Relevance
CIS Controls v8	CIS-5 — Account Management	Modern prescribing still relies on controlled access and workflow discipline.
Recommendation — Standardize access and exception handling so manual prescribing paths stay tightly governed.
NIST SP 800-53 Rev 5	AU-2 — Audit Events	Dual workflows need traceability to show what path each order took.
Recommendation — Log prescribing path, exception, and handoff events for review and reconciliation.
ISO/IEC 27001:2022	A.5.15 — Access control	Controlled workflows need clear access and process boundaries to reduce ad hoc handling.
Recommendation — Define and enforce the approved prescribing path with documented exceptions.

Practitioner Guidance

What to verify: Check whether paper use is truly exceptional or whether it is covering for workflow friction, integration gaps, or weak adoption. If exceptions are frequent, the problem is usually process design rather than user reluctance alone.

What to measure: Track the share of prescriptions that still require manual intervention, the number of handoffs per order, and how often patients must return to the pharmacy because the first pass failed. Those signals show whether modernization is real or merely installed.

Common mistake: Treating technology availability as modernization. A system is not modern just because it exists, it is modern when people can use it consistently without reverting to parallel manual paths.

Practitioner takeaway: The best indicator of modernization is not deployment, but whether the workflow has become the default, low-friction, low-exception path for clinicians, staff, and patients.